A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder

Summary

Major depressive disorder (MDD; depression) is a mood disorder that causes a continued feeling of sadness and loss of interest. It is a common and serious illness that can cause both emotional and physical symptoms such as feelings of sadness, irritability, not being able to focus on activities, tiredness, changes in eating habits, and aches and pains. This study will assess the changes in disease activity and adverse events of oral Icalcaprant in adult participants with major depressive disorder who are currently experiencing a major depressive episode (MDE).

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Major Depressive Disorder

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2

Ages

18 to 65 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

AbbVie

Last updated on ClinicalTrials.gov

June 15, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites